High Heart Rate Clinical Trial
Official title:
Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate
A significant association between resting heart rate (HR) and both all-cause mortality and
cardiovascular mortality has been demonstrated in numerous epidemiologic studies for both
the general population and for patients with cardiovascular disease.
Cardiac disease is the leading cause of death among hemodialysis (HD) patients a recent
study reported that the 48-hr mean HR is an independent predictor of cardiovascular events
in normotensive hemodialysis patients.
Ivabradine, a pure HR lowering agent,acting on If current inhibition has proven beneficial
antianginal effects and mortality reduction linked to HR reduction in ischemic patients.
Aim:
To evaluate the safety and efficacy of ivabradine in normotensive hemodialysed patients with
increased pre-dialysis HR (> 80 bpm)
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment